1.03
0.98%
+0.01
After Hours:
1.03
IN8bio Inc stock is currently priced at $1.03, with a 24-hour trading volume of 37,482.
It has seen a +0.98% increased in the last 24 hours and a +3.00% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.06 pivot point. If it approaches the $0.9633 support level, significant changes may occur.
Previous Close:
$1.02
Open:
$1.04
24h Volume:
37,482
Market Cap:
$45.45M
Revenue:
-
Net Income/Loss:
$-30.01M
P/E Ratio:
-0.8443
EPS:
-1.22
Net Cash Flow:
$-23.94M
1W Performance:
+1.98%
1M Performance:
+3.00%
6M Performance:
+13.19%
1Y Performance:
-62.95%
IN8bio Inc Stock (INAB) Company Profile
Name
IN8bio Inc
Sector
Industry
Phone
646 600 6438
Address
350 5th Avenue, Suite 5330, New York
IN8bio Inc Stock (INAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-30-22 | Initiated | H.C. Wainwright | Buy |
IN8bio Inc Stock (INAB) Latest News
The Future of IN8bio Inc: Analyzing INAB - The InvestChronicle
The InvestChronicle
IN8bio (NASDAQ:INAB) Price Target Cut to $12.50 - Defense World
Defense World
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress - GlobeNewswire
GlobeNewswire
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ... - GlobeNewswire
GlobeNewswire
IN8bio (INAB) Stock Forecast and Price Target 2024 - MarketBeat
MarketBeat
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Yahoo Finance
Yahoo Finance
IN8bio Inc Stock (INAB) Financials Data
IN8bio Inc (INAB) Net Income 2024
INAB net income (TTM) was -$30.01 million for the quarter ending December 31, 2023, a -5.21% decrease year-over-year.
IN8bio Inc (INAB) Cash Flow 2024
INAB recorded a free cash flow (TTM) of -$23.94 million for the quarter ending December 31, 2023, a +13.97% increase year-over-year.
IN8bio Inc (INAB) Earnings per Share 2024
INAB earnings per share (TTM) was -$1.01 for the quarter ending December 31, 2023, a +25.74% growth year-over-year.
About IN8bio Inc
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Cap:
|
Volume (24h):